Emma Stolyar, DO
Family Medicine · Brooklyn, NYNPI 1457399008
Payments from drug & device makers
Across 170 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$721
- Kowa Pharmaceuticals America, Inc.$499
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$464
- Amarin Pharma, Inc.$364
- Amgen$342
- Novo Nordisk$142
- plus $623 from 15 others
What the payments were for
- Speaking & faculty fees$140%
- Food & beverage$3,10498%
- Education$351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 38 | $721 |
| Kowa Pharmaceuticals America, Inc. | 22 | $499 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 32 | $464 |
| Amarin Pharma, Inc. | 22 | $364 |
| Amgen(2 entities) | 18 | $342 |
| Novo Nordisk | 7 | $142 |
| AstraZeneca | 5 | $110 |
| Lilly USA, LLC | 5 | $77 |
| GSK | 3 | $64 |
| Pfizer | 3 | $57 |
| Nestle Healthcare Nutrition Inc. | 3 | $56 |
| Impel Pharmaceuticals Inc. | 2 | $48 |
| Shield Therapeutics Inc | 2 | $46 |
| Biohaven Pharmaceuticals, Inc. | 1 | $29 |
| Aimmune Therapeutics, Inc. | 1 | $28 |
| Johnson & Johnson | 1 | $21 |
| Vivus LLC | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $18 |
| Merck | 1 | $15 |
| Medicure Pharma Inc. | 1 | $14 |
How this compares
$3,154 in reported general payments places this provider in the 80th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clemastine Fumarate | 33 | $234,283 |
| ZenpepLipase/Protease/Amylase | 125 | $181,731 |
| LinzessLinaclotide | 248 | $136,008 |
| CreonLipase/Protease/Amylase | 109 | $122,334 |
| VascepaIcosapent Ethyl | 333 | $111,378 |
| Dihydroergotamine Mesylate | 62 | $101,415 |
| OzempicSemaglutide | 111 | $98,470 |
| Diclofenac Sodium | 208 | $96,634 |
| Metformin Er GastricMetformin Hcl | 48 | $91,332 |
| JanumetSitagliptin Phos/Metformin Hcl | 134 | $78,476 |
| EliquisApixaban | 114 | $74,990 |
| TrulicityDulaglutide | 53 | $57,010 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 39 | $55,954 |
| JardianceEmpagliflozin | 86 | $55,879 |
| MyrbetriqMirabegron | 109 | $46,910 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon, Ubrelvy, Namzaric, Qulipta | $721 | $364,294480 claims |
| Aimmune Therapeutics, Inc.Zenpep | $28 | $181,731125 claims |
| Novo NordiskOzempic | $142 | $98,470111 claims |
| MerckJanumet, Steglatro | $15 | $93,984167 claims |
| PfizerEliquis, Nurtec Odt | $57 | $89,732125 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $77 | $84,20180 claims |
| AstraZenecaFarxiga, Nexium | $110 | $32,73670 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $64 | $28,69349 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $499 | $15,44233 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $464 | $14,05226 claims |
| Johnson & JohnsonXarelto | $21 | $11,38317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,321 family medicine providers in New York.
Other family medicine in Brooklyn
- Michael YuryevBrooklyn$589K
- Matthew SpitzerBrooklyn$469K
- Walford LindoBrooklyn$104K
- Fu Fu HeBrooklyn$101K
- Jonathan ChangBrooklyn$66K
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.